ByHeart, Inc., Infant Formula

The ByHeart, Inc., Infant Formula litigation, centralized before Judge Arun Subramanian in the Southern District of New York in April 2026, consolidates claims arising from a nationwide recall of ByHeart infant formula following contamination findings linked to reports of infant illness. With just 22 total actions filed roughly five months after centralization, this is a very young docket that combines a marketing and sales-practices theory — that the product was sold and represented as safe despite the contamination — with a personal-injury products-liability tail for infants who became ill after consuming the recalled formula.

At this early stage, there is no bellwether trial record, general-causation ruling, or settlement framework to price against, so funding decisions rest almost entirely on individual claim documentation: which specific lot or batch of formula was consumed, the timeline and severity of the infant's illness, and pediatric medical records establishing the connection between consumption and the alleged harm. Because the claim population remains small, portfolio-style diversification offers limited benefit compared with a mature mass tort, making single-claim or small-batch funding structures more appropriate at this stage.

Medical-lien exposure in infant-illness claims tied to a contamination event can include hospitalization, pediatric specialist care, and any ongoing monitoring recommended after a serious infant illness, and that exposure should be sized carefully even for a docket this young. Given the litigation's early posture, funding terms should be structured for a longer expected duration than a mature docket would require, with pricing anchored to the strength of individual medical and product-identification records. Criterica Capital's mass tort finance product is the relevant path for claims tied to this litigation as it develops, and a structural brief on the docket's early formation is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.